Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ONO 4685

Next Previous
Drug Profile

ONO 4685

Alternative Names: ONO-4685

Latest Information Update: 27 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merus; Ono Pharmaceutical
  • Developer Ono Pharmaceutical
  • Class Antineoplastics; Antipsoriatics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD3 antigen inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders; Chronic lymphocytic leukaemia; Plaque psoriasis; T-cell lymphoma

Most Recent Events

  • 18 Jul 2024 Ono Pharmaceutical completes a phase-I trial in Plaque psoriasis (In adults, In the elderly) in Romania, Moldova and United Kingdom (IV), (NCT05332704)
  • 13 May 2024 Ono Pharmaceutical suspends a phase I trial in Plaque psoriasis in Romania, Moldova, and United Kingdom (IV), due to the protocol-defined stopping criterion being met (NCT05332704)
  • 25 Aug 2023 Ono Pharmaceutical resumes enrolment in its previously suspended phase I trial in Plaque psoriasis (In adults, In the elderly) in Moldova (IV) (NCT05332704)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top